Medication info
Durotel Tablet 40/20 mg

Durotel Tablet 40/20 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium Micronized›20.8mg / 1 tablet
Manufacturer / importer
Withus Pharmaceutical Co., Ltd.
Appearance
Light pink oval film-coated tablet
Packaging
30 boxes / box [10 tablets / Alu-Alu x 3]
Approval status
Active

MFDS item code 202103315 · Approved 2021.04.22 · Insurance code 660703610

Summary

Main use
Treatment of hypertension and dyslipidemia; prevention of cardiovascular disease and inhibition of the progression of atherosclerosis
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered in combination with a thiazide diuretic such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reducing effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product with the same amount of each active ingredient) for convenience.

Ingredients

Manufacturer
Withus Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; prevention of cardiovascular disease and inhibition of the progression of atherosclerosis

  • Essential hypertension
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used in patients who need to take both telmisartan and rosuvastatin. Telmisartan helps to treat essential hypertension and reduce the risk of cardiovascular diseases. It is especially effective in older patients with a high risk of myocardial infarction, stroke, and death related to cardiovascular diseases, as well as patients with diabetes. Rosuvastatin is used to treat hypercholesterolemia and dyslipidemia when they are not adequately controlled by diet and exercise. It also contributes to slowing the progression of atherosclerosis and reducing the risk of cardiovascular disease. By combining both medications, blood pressure and blood lipid levels are effectively improved, thus managing cardiovascular health.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered in combination with a thiazide diuretic such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reducing effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product with the same amount of each active ingredient) for convenience.

Precautions

This medication may cause serious harm to the fetus and newborn, especially during pregnancy, so it must be discontinued immediately if pregnancy is confirmed. It should not be used in individuals with hypersensitivity to this medication, women who are pregnant or nursing, and women of childbearing age who are not using adequate contraception. It is safer not to administer it to patients with severely impaired liver function or problems with bile secretion, as well as to patients with certain liver diseases. Patients with muscle disorders or hereditary angioedema, those with severely impaired kidney function, and those taking certain medications should not use this medication. Caution is required for the elderly, patients with hyperkalemia, and patients with slightly impaired liver function, and regular liver function and muscle-related tests should be conducted. If symptoms such as muscle pain or weakness occur, consult a doctor immediately and stop taking the medication if necessary. This medication may affect the liver and kidneys, so it is important to regularly check liver enzymes and kidney function with blood tests. The risk of side effects may be increased when taken with other antihypertensive agents or certain lipid-lowering medications, so patients must inform their doctor about any other medications they are taking. This medication may cause drowsiness or dizziness, so caution is required when driving or operating dangerous machinery. It is not recommended for children, as safety and efficacy have not been established. In cases of overdose, symptoms may include hypotension, dizziness, acute renal failure, and medical personnel should be contacted immediately. This medication should be kept out of reach of children, and care should be taken not to transfer it to other containers.

Side effects

Increased ALT, Increased AST, Increased serum creatine phosphokinase (CPK), Dizziness, Itching, Indigestion, Oral paresthesia, Musculoskeletal rigidity, Acne, Nasopharyngitis, Dysuria, Rhinitis, Oropharyngeal discomfort, Lung disease, Unspecified gastroenteritis, Benign gastrointestinal neoplasm, Hemorrhoids, Skeletal pain, Osteoporosis, Sensory loss, Dyskinesia, Atherosclerosis, Frequent urination, Tinnitus, Hearing loss, Halitosis, Fatty liver, Upper respiratory tract infection, Urinary tract infection, Sepsis, Anemia, Thrombocytopenia, Eosinophilia, Hypersensitivity, Anaphylactic reaction, Hyperkalemia, Hypoglycemia, Depression, Insomnia, Anxiety, Syncope, Visual disturbances, Dizziness, Bradycardia, Tachycardia, Hypotension, Orthostatic hypotension, Dyspnea, Abdominal pain, Diarrhea, Abdominal distension, Vomiting, Abdominal discomfort, Dry mouth, Liver function abnormalities, Hepatic impairment, Increased sweating, Rash, Erythema, Angioedema, Drug rash, Toxic epidermal necrolysis, Eczema, Urticaria, Myalgia, Low back pain, Muscle cramps, Arthralgia, Limb pain, Tendon pain, Acute kidney failure, Chest pain, Asthenia, Influenza-like illness, Increased serum creatinine, Increased serum uric acid, Increased liver enzymes, Elevated serum CK, Decreased hemoglobin, Hypoglycemia, Angioedema, Hypersensitivity reaction, Diabetes, Headache, Constipation, Nausea, Pancreatitis, Itching, Rash, Urticaria, Myopathy, Rhabdomyolysis, Asthenia, Polyneuropathy, Amnesia, Peripheral neuropathy, Cough, Jaundice, Hepatitis, Stevens-Johnson syndrome, Eosinophilia with systemic symptoms drug reaction syndrome, Lupus-like syndrome, Muscle rupture, Immune-mediated necrotizing myopathy, Hematuria, Edema, Depression, Sleep disorders, Sexual dysfunction, Gynecomastia, Fatal and non-fatal liver failure, Cognitive impairment, Severe muscle weakness, Ocular muscle weakness, Headache, Facial spasms, Paresthesia, Paralysis, Hyperventilation, Pneumonia, Flushing, Erectile dysfunction, Loss of appetite, Arrhythmia, Weakness, Edema, Decreased libido, Facial edema, Alopecia, Conjunctivitis, Tinnitus, Petechiae, Headache, Dizziness, Cough, Palpitations, Nausea, Inadequate effect, Joint pain, Fatigue, Numbness, Paresthesia, Chest discomfort, Loss of appetite, Abdominal distension, Syncope, Widespread pain, Muscle cramps, Gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. Avoid storing it in excessively hot or cold places, and it is recommended to store it at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Light pink oval film-coated tablet

Package unit

30 boxes / box [10 tablets / Alu-Alu x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.